Dr. Barry Gertz is a Venture Partner at Clarus Ventures, a healthcare investment firm in Boston, MA. Prior to his role at Clarus, Dr. Gertz was Senior Vice President and Head of Global Clinical Development, overseeing all aspects of Merck’s clinical research. He has 28 years of experience in drug development, from exploratory clinical pharmacology to global phase 3 trials. While at Merck, Dr. Gertz was instrumental in the development and approval of more than 25 new drugs and vaccines, including the blockbuster products Fosamax and Januvia. Dr. Gertz has co-authored over a hundred scientific publications appearing in the Journal of Clinical Investigation, the Journal of Clinical Endocrinology and Metabolism, and the New England Journal of Medicine. Dr. Gertz received an MD, PhD, and BA from the University of Pennsylvania, and subsequently trained in internal medicine at the Hospital of the University of Pennsylvania and held fellowship and faculty positions at UCSF.